孕酮合成相关基因多态性与长方案GnRH激动剂中孕酮升高的关系
研究纳入765例接受长方案GnRH激动剂促排卵的女性,按HCG日血清孕酮浓度第75百分位分为高孕酮组与正常孕酮组,分析全外显子测序基因信息与临床特征。结果显示40个常见SNP经FDR校正后与孕酮升高无显著关联,但CYP17A1单倍型GAAG与孕酮升高风险增加相关,FSHR、LHCGR、ESR1、ESR2和HSD3B1的特定单倍型与风险降低相关。
要点
- 40个常见SNP经FDR校正后与HCG日孕酮升高无显著关联。
- CYP17A1单倍型GAAG与孕酮升高风险增加1.44倍相关。
- FSHR、LHCGR、ESR1、ESR2和HSD3B1特定单倍型与孕酮升高风险降低相关。
核心结论
- 孕酮合成通路中酶或激素受体相关基因的多态性可能改变血清孕酮升高的风险。
研究设计与样本
- 研究纳入765例接受长方案GnRH激动剂促排卵的女性,按HCG日血清孕酮浓度第75百分位分为高孕酮组与正常孕酮组。
主要发现
- 8个基因(FSHR、LHCGR、ESR1、ESR2、PGR、HSD3B1、CYP11A1和CYP17A1)的40个常见SNP经FDR校正后,高孕酮组与正常孕酮组的基因型和等位基因频率分布无统计学显著差异(PFDR > 0.05)。
- 与各基因最常见单倍型相比,CYP17A1单倍型GAAG与孕酮升高风险增加1.44倍相关(95%CI 1.22-1.69,PFDR < 0.001)。
- FSHR和LHCGR单倍型CC与孕酮升高风险降低相关(分别为0.66倍,PFDR = 0.020;0.64倍,PFDR < 0.001)。
- ESR1单倍型CA(0.90倍,PFDR < 0.001)、ESR2单倍型TCTGG(0.92倍,PFDR = 0.007)和HSD3B1单倍型GAACC(0.42倍,PFDR < 0.001)与孕酮升高风险降低相关。
关键数值与推荐
- 高孕酮组与正常孕酮组以HCG日血清孕酮浓度第75百分位为阈值划分。
- CYP17A1单倍型GAAG与孕酮升高风险增加1.44倍相关(95%CI 1.22-1.69,PFDR < 0.001)。
- FSHR单倍型CC与孕酮升高风险降低相关(0.66倍,PFDR = 0.020)。
- LHCGR单倍型CC与孕酮升高风险降低相关(0.64倍,PFDR < 0.001)。
- HSD3B1单倍型GAACC与孕酮升高风险降低相关(0.42倍,PFDR < 0.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Can single-nucleotide polymorphisms (SNP) of genes related to progesterone synthesis predict the risk of premature serum progesterone elevation in women undergoing gonadotrophin-releasing hormone agonist protocols for ovarian stimulation? DESIGN: A total of 765 women were divided into high progesterone and normal progesterone groups according to progesterone concentration on the day of human chorionic gonadotrophin (HCG) administration, with the 75th percentile as the threshold between the group. Associations were analysed of genetic information from whole exome sequencing and the clinical characteristics of the two groups to identify the relationship between SNP, haplotypes and serum progesterone elevation. RESULTS: Among 40 common SNP of eight genes (FSHR, LHCGR, ESR1, ESR2, PGR, HSD3B1, CYP11A1 and CYP17A1), no statistical significance between the high and normal progesterone groups was identified in the distribution of genotypes and allele frequencies after multiple test correction to adjust the false discovery rate (PFDR > 0.05). When compared with the most common haplotypes of each gene, haplotype GAAG in CYP17A1 was associated with a 1.44-fold increased risk of progesterone elevation (95% confidence interval [CI] 1.22-1.69, PFDR < 0.001), while haplotypes of the following genes showed a decreased risk of progesterone elevation: haplotype CC in FSHR and LHCGR (0.66-fold, PFDR = 0.020, and 0.64-fold, PFDR < 0.001, respectively), CA in ESR1 (0.90-fold, PFDR < 0.001), TCTGG in ESR2 (0.92-fold, PFDR = 0.007) and GAACC in HSD3B1 (0.42-fold, PFDR < 0.001). CONCLUSIONS: Polymorphism in genes involved in enzymes or hormone receptors in the progesterone synthesis pathway may have a role in modifying risk of serum progesterone elevation.
引用
- Cao P, Miao B, Xu Y, et al. Role of gene polymorphisms related to progesterone elevation in women undergoing long GnRH agonist protocols. Reprod Biomed Online. 2019. PMID: 32204850. doi:10.1016/j.rbmo.2019.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。